Showing results (2411-2420 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|March 15, 2024
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature ReviewAngie Raad, Maria Rizzo, Katherine Appiah, et al.
Pharmacoeconomics|April 1, 2024
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology AssessmentsJen-Yu Amy Chang, James B Chilcott, Nicholas R Latimer
Pharmacoeconomics|February 1, 2024
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USAShih-Wen Lin, Sheila Shapouri, Hélène Parisé, et al.
Pharmacoeconomics|July 28, 2023
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and ValidationPeter Gal, Gyorgyi Feldmajer, Margarida Augusto, et al.
Pharmacoeconomics|March 21, 2026
The Cost Utility of Rhythm Control Treatment Sequences in Patients with Atrial Fibrillation: Anti-arrhythmic Drugs Versus Catheter AblationSimone Huygens, Matthijs Versteegh, Martin Hemels, et al.
Pharmacoeconomics|May 10, 2024
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic ReviewClazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, et al.
Pharmacoeconomics|April 29, 2024
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United StatesWilliam L Herring, Meghan E Gallagher, Nirmish Shah, et al.
Pharmacoeconomics|October 27, 2023
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology AssessmentsAlex J Turner, Cormac Sammon, Nick Latimer, et al.
Pharmacoeconomics|November 1, 2023
Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population StudyJavier Mar, Oliver Ibarrondo, Carlo Delfin S Estadilla, et al.
Pharmacoeconomics|September 2, 2023
Modelling Spillover Effects on Informal Carers: The Carer QALY TrapDavid J Mott, Hannah Schirrmacher, Hareth Al-Janabi, et al.
Pageof 336